Health Services Research

You have full text access to this OnlineOpen article

Impact of medicare part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis

  1. Jennifer M. Polinski1,*,
  2. Penny E. Mohr2,
  3. Lorraine Johnson3

Article first published online: 28 MAY 2009

DOI: 10.1002/art.24560

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 61, Issue 6, pages 745–754, 15 June 2009

Additional Information

How to Cite

Polinski, J. M., Mohr, P. E. and Johnson, L. (2009), Impact of medicare part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis. Arthritis & Rheumatism, 61: 745–754. doi: 10.1002/art.24560

Author Information

  1. 1

    Brigham and Women's Hospital, Boston, Massachusetts

  2. 2

    Center for Medical Technology Policy, Baltimore, Maryland

  3. 3

    Centers for Medicare and Medicaid Services, Baltimore, Maryland

*Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120

Publication History

  1. Issue published online: 28 MAY 2009
  2. Article first published online: 28 MAY 2009
  3. Manuscript Accepted: 25 FEB 2009
  4. Manuscript Received: 25 AUG 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (334K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Chris Pease, Janet E. Pope, Don Truong, Claire Bombardier, Jessica Widdifield, J. Carter Thorne, Boulos Paul Haraoui, Eliofotisti Psaradellis, John Sampalis, Ashley Bonner, Comparison of Anti-TNF Treatment Initiation in Rheumatoid Arthritis Databases Demonstrates Wide Country Variability in Patient Parameters at Initiation of Anti-TNF Therapy, Seminars in Arthritis and Rheumatism, 2011, 41, 1, 81

    CrossRef

  2. 2
    Salimah H. Meghani, Corporatization of Pain Medicine: Implications for Widening Pain Care Disparities, Pain Medicine, 2011, 12, 4
    Direct Link:
  3. 3
    Carlo A. Marra, Nick Bansback, Aslam H. Anis, Kamran Shojania, Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis, Clinical Rheumatology, 2011, 30, S1, 9

    CrossRef

  4. 4
    Leslie Jackson Conwell, Dominick Esposito, Margaret Colby, Daniel Ball, Eric S. Meadows, Martin Marciniak, Promising therapies, prohibitive costs: a qualitative assessment of the effects of the Medicare Part D doughnut hole on access to costly cancer medications, Community Oncology, 2011, 8, 3, 111

    CrossRef

  5. 5
    Jeffrey R. Curtis, Jasvinder A. Singh, Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care, Clinical Therapeutics, 2011, 33, 6, 679

    CrossRef

  6. 6
    Michael M. Ward, Medicare reimbursement and the use of biologic agents: Incentives, access, the public good, and optimal care, Arthritis Care & Research, 2010, 62, 3
    Direct Link:
View Full Article (HTML) Get PDF (334K)